Predicting P-Glycoprotein Substrates by a Quantitative Structure-Activity Relationship Model

Journal of Pharmaceutical Sciences

Volumn 93, Issue 4, 2004, Pages 957-968

  Gombar, Vijay K ^a   Polli, Joseph W ^b   Humphreys, Joan E ^b   Wring, Stephen A ^b,c   Serabjit Singh, Cosette S ^b  

^a MV CEDD ^*  (United States)

^b GLAXOSMITHKLINE   (United States)

^c PreClinical DMPK   (United States)

Author keywords

Absorption; Blood brain barrier; Metabolism; Multi drug resistance; P glycoprotein; QSAR; Transporter

Indexed keywords

AMANTADINE; AMPRENAVIR; CALCEIN; CHLOROQUINE; CHLORPHENIRAMINE; CHLORPROMAZINE; CIMETIDINE; CLARITHROMYCIN; COLCHICINE; CYCLOSPORIN A; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DIGOXIN; DILTIAZEM; DIPYRIDAMOLE; DOXORUBICIN; ELETRIPTAN; EMETINE; ERYTHROMYCIN; ETOPOSIDE; GLYCOPROTEIN P; INDINAVIR; LIDOCAINE; MANNITOL; MIDAZOLAM; PACLITAXEL; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

ACCURACY; ARTICLE; BLOOD BRAIN BARRIER; CALCULATION; CHEMICAL BOND; COMPUTER MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSPORT; EFFUSION; ELECTROPORATION; IN VITRO STUDY; MATHEMATICAL MODEL; MEMBRANE; MULTIDRUG RESISTANCE; PARTITION COEFFICIENT; PERMEABILITY; PREDICTION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VALIDATION PROCESS;

EID: 1842586876     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20035     Document Type: Article

References (33)

1. Borst P, Oude Elferink R. 2002. Mammalian ABC transporters in health and human disease. Annu Rev Biochem 71:537-592.
2. Schinkel AH, Jonker JW. 2002. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Del Rev 55:3-29.
3. Lin JH, Yamazaki M. 2003. Role of P-glycoprotein in pharmacokinetics. Clin Pharmacokinet 4:59-98.
4. Fromm MF. 2000. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmarcol Ther 38:69-74.
5. Seelig A. 1998. A general pattern for substrate recognition of P-glycoprotein. Eur J Biochem 251:252-261.
6. Seelig A, Landwojtowicz E. 2000. Structure-activity relationship of P-glycoprotein substrates and modifers. Eur J Pharm Sci 12:31-41.
7. Stouch TR, Gudmundsson O. 2002. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Del Rev 54:315-328.
8. Ekins S, Waller C, Swann PW, Cruciani G, Wrighton SA, Wikel JH. 2000. Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Meth 44:251-272.
9. Zhang EY, Phelps MA, Cheng C, Ekins S, Swaan PW. 2002. Modeling active transport systems. Adv Drug Del Rev 54:329-354.
10. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. 2002. Passive permeability and P-glycoprotein mediated efflux differentiate CNS and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037.
11. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL. 1999. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 16:1206-1212.
12. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
13. Smith BJ, Doran AC, McLean S, Tingley FD III, O'Neill BT, Kajiji AM. 2001. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. J Pharmacol Exp Ther 298:1252-1259.
14. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O. 1997. Limited oral bioavailability and active epithelial excretion of paclitaxel (taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
15. Verschraagen M, Koks CH, Schellens JH, Beijnen JH. 1999. P-glycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil. Pharmacol Res 40:301-306.
16. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CJ. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
17. Hall L, Mohney B, Kier L. 1991. The electrotopological state: Structure information at the atomic level. J Chem Inf Comput Sci 31:76-82.
18. Gombar VK, Silver IS, Zhao Z. 2003. Role of ADME characteristics in drug discovery and their in silico evaluation: In silico screening of chemicals for their metabolic stability. Curr Top Med Chem 3:1205-1225.
19. Tetko IV, Tanchuk VY, Villa AEP. 2001. Prediction of n-octanol/water partition coefficients from PHY-SPROP databse using artificial neural networks and E-state indices. J Chem Inf Comput Sci 41:1407-1421.
20. Gombar VK. 1999. Reliable assessment of LogP of compounds of pharmaceutical relevance. SAR QSAR Env Res 10:371-380.
21. Gough JD, Hall LH. 1999. Modeling antileukemic activity of carboquinones with electrotopological state and chi indices. J Chem Inf Comput Sci 39:356-361.
22. Kellogg GE, Kier LB, Hall LH. 1996. The E-state fields. Applications to 3-D QSAR. J Comp-Aided Mol Des 10:513-520.
23. Kier LB, Hall LH. 1999. Molecular structure description: The electrotopological state. San Diego, USA: Academic Press.
24. Kier L. 1986. Shape indices of orders one and three from molecular graphs. Quant Struct Act Relat 5:1-7.
25. Lipinski CA. 2000. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235-249.
26. Gombar VK, Hiemenz BJ. VInRTP - very information rich topological parameters - a web-based structure quantification system (In house software, GlaxoSmithKline, Inc., Research Triangle Park, NC 27709).
27. BMDP New System 2.0. 2001. © 2001, Statistical Solution, Ltd., Stonehill Corporate Center, Suite 104, 999 Broadway, Saugus, MA 01906, USA.
28. SAS 8.01 TS Level 01M0. 1999. © 1999, SAS Institute, Inc., SAS Campus Drive, Cary, NC, 27513, USA.
29. Lee K, Ng C, Brouwer KL, Thakker DR. 2002 Secretory transport of ranitidine and famotidine across Caco-2 cell monolayers. J Pharmacol Exp Ther 303:574-580.
30. Eytan GD, Regev R, Oren G, Assaraf YG. 1996. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem 271:12897-12902.
31. Ferte J. 2000. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem 267:277-294.
32. Tolle-Sander S, Rautio J, Wring S, Polli JW, Polli JE. 2003. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 20:757-764.
33. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE. 2000. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res 17:1456-1460.